|
 |
|
|
|||
|
 |
|
Nov. 4, 2025 Source: Zoetis news release PARSIPPANY, N.J.-- Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025. The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 2024. Net income for the third quarter of 2025 was $721 million, or $1.63 per diluted share, an increase of 6% and 9%, respectively, on a reported basis. Adjusted net income2 for the third quarter of 2025 was $754 million, or $1.70 per diluted share, an increase of 5% and 8%, respectively, on a reported basis, and an increase of 9% and 12%, respectively, on an organic operational basis. Adjusted net income for the third quarter of 2025 excludes the net impact of $33 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. EXECUTIVE COMMENTARY "We reported 4% organic operational revenue growth and 9% growth in adjusted net income on an organic operational basis, thanks to the relentless focus and consistent execution of our colleagues across the world," said Kristin Peck, Chief Executive Officer of Zoetis. "While growth moderated in the third quarter in line with our expectations, we achieved significant regulatory milestones, including major new product approvals, geographic expansions and differentiating lifecycle innovations across products and species. With our manufacturing excellence, strong customer relationships and a robust pipeline, we are well positioned to advance animal care, bring new products to market and deliver sustainable growth and value for our shareholders." Supporting Livestock Customers To address an urgent threat facing U.S. livestock producers, Zoetis received a conditional approval from the Food and Drug Administration (FDA) for Dectomax-CA1 Injectable for the prevention and treatment of New World screwworm myiasis in cattle. This new label makes it the first and only parasite control product with conditional approval to help control this economically devastating pest. Synovex Primer received approval in Canada for an additional claim to increase rate of weight gain in growing beef steers and heifers on pasture. It also received approval in Mexico for use on pasture, confinement and in the backgrounder phase. In the UK, the company received approval for a needle-free microdose of Suvaxyn PRRS, a vaccine that helps prevent porcine respiratory and reproductive syndrome. To read the entire report click here. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
